PR
Media
-
HEM Pharma acquired ‘Innobiz Grade A’, a technology innovation certification sys..2022.10.28 -
Sejong City attracts 598.2 billion won investment with 13 semiconductor and med..2022.09.30 -
Special lecture on 'Live Biotherapeutic Product (LBP) development and technolog..2022.09.21 -
[Amway's persistent interview] New concept health platform "Microbiome solu..2022.08.12 -
HEM Pharma, selected as a reserve unicorn by the Ministry of SMEs and Startups...2022.07.05 -
Provide optimized and personalized health solutions2022.05.24 -
HEM Pharma, Amway Korea to launch customized microbiome solution2022.05.20 -
Amway Korea, enters the customized microbiome solution market2022.05.20 -
HEM Pharma, completes payment of 10.9 billion won worth of third-party capital ..2022.05.20 -
HEM Pharma, Registered a domestic patent for atopic dermatitis, enteritis, and c..2022.04.21 -
HEM Pharma, Pioneering new markets with high value-added microbiome technology2022.03.20 -
HEM Pharma, acquires US patent for ‘customized screening technology for improvi..2022.03.15
- Headquarters
-
Address. #711, Flex Desiang, 50, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
- Gwanggyo Office
- Address. #404, Ace Gwanggyo Tower 3, 77, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
(C) 2022.HEM Pharma Inc. All rights reserved.